Skip to content
← Full study record

NCT01946204 · MORE INFO

Limitations, agreements, and source contact

A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer · Source last updated 2026-08-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
These results are up to clinical cutoff (CCO) date (that is, 19 May 2017).
point Of Contact
email
ClinicalTrialDisclosure@its.jnj.com
organization
Janssen Research & Development, LLC
phone
844-434-4210
title
Senior Medical Director, WC Clinical Oncology Department
Complete source fields
certain Agreement
other Details
A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
These results are up to clinical cutoff (CCO) date (that is, 19 May 2017).
point Of Contact
email
ClinicalTrialDisclosure@its.jnj.com
organization
Janssen Research & Development, LLC
phone
844-434-4210
title
Senior Medical Director, WC Clinical Oncology Department

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice